Inquiry · Opened 5 March 2026
China and the UK economy
From: Business and Trade Committee
What this inquiry is asking
This inquiry examines how deeply the UK economy is entangled with China, what opportunities exist in Chinese markets, and what risks that dependence creates for British businesses, universities, and security. The committee is testing whether the UK should deepen engagement with China or reduce exposure through supply chain diversification and regulatory safeguards.
Status / emerging findings
- Only 19% of Make UK members export directly to China; 49% have already begun reshoring supply chains away from China over five years, driven by semiconductor crises and energy shocks rather than government policy
- Russell Group universities derive up to 50% of international student revenue from China but lack financial resilience beyond four years if recruitment stopped; this represents existential risk despite government silence on contingency
- UK-China goods deficit has doubled from £20bn (2019) to £50bn (2025) with no reversal in sight, yet witnesses argue trade remains beneficial for consumers and supply chain integration
- AstraZeneca's $15bn China investment announced during PM visit while executive prosecution was live raises questions about whether geopolitical pressure, not commercial logic, drove the decision
- Tech firms operate in policy 'grey zone' lacking coordinate government guidance on data localisation and IP protection; financial services exports to China represent only 3% of total but growing middle class offers long-term opportunity
Why it matters
The UK's economic exposure to China is deepening even as political risk intensifies; universities and manufacturers face real financial jeopardy from disruption, yet government sends conflicting signals on whether to engage or diversify away.
Tone arc
Began with business-led optimism about Chinese market access (Session 1: CBI/CBBC emphasis on engagement necessity), shifted toward critical scrutiny of geopolitical leverage and financial vulnerabilities (Sessions 2–3 exposed AstraZeneca timing questions, university financial fragility, and government incoherence across departments).
Themes
Key witnesses
Rain Newton-Smith (CBI), Peter Burnett OBE (China-Britain Business Council), Miles Celic OBE (financial services), Professor Sir Peter Mathieson MBBS(Hons) (universities), Sabina Ciofu (tech), James Brougham (manufacturing), Julian Scriven (Brompton Bicycles)
Witness sessions
Oral evidence · 21 April 2026 · HC 1767
Session 1 of 6Oral evidence · 21 April 2026 · HC 1767
Session 2 of 6Miles Celic OBE; Professor Sir Peter Mathieson MBBS(Hons); Sabina Ciofu
Oral evidence · 21 April 2026 · HC 1767
Session 3 of 6Oral evidence · 19 May 2026 · HC 124
Session 4 of 6Oral evidence · 19 May 2026 · HC 124
Session 5 of 6Oral evidence · 19 May 2026 · HC 124
Session 6 of 6Silvia Gavornikova; University of Oxford China Centre; Soumaya Keynes; +3 more
Written evidence & correspondence
Themes & actors
Topics across publication summaries
Top organisations & named entities
- Professor Sir Peter Mathieson·1 reference
- University of Edinburgh·1 reference
- Liam Byrne MP·1 reference
- Business and Trade Committee·1 reference
- Research Collaboration Advice Team (RCAT)·1 reference
- Russell Group·1 reference
- Department for Education·1 reference
- Universities UK·1 reference
Source · parliament.uk inquiry record ↗